Health
Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics, Labcorp plans to make the test available nationwide by early 2026.
About this update from Labcorp Holdings Inc.
[{"type":"text","content":"Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics, Labcorp plans to make the test available nationwide by early 2026.","length":494,"tagName":"p"},{"type":"image","alt":"Labcorp Logo (PRNewsfoto/Labcorp)","displaySize":"","headline":null,"caption":"Labcorp Logo (PRNewsfoto/Labcorp)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Cr5Hwp2W1WfQXLeh2BBTbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549","width":400,"height":107}},"href":"https://mma.prnewswire.com/media/2044800/Labcorp_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"An estimated 7.2 million Americans are living with Alzheimer's disease, a number expected to nearly double by 2050. Cognitive changes are often first identified during routine care visits, but Alzheimer's biomarker testing has traditionally required a specialist referral and advanced invasive testing. The Elecsys pTau181 test is intended for adults ages 55 and older with signs, symptoms or complaints of cognitive decline. Clinicians can order the test to help rule out Alzheimer's-related amyloid pathology and identify patients who may benefit from further evaluation.","length":595,"tagName":"p"},{"type":"text","content":""Many patients presenting with cognitive symptoms don't have Alzheimer's disease, so helping clinicians rule it out can be just as critical as confirming it," said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. "As a leader in neurology with the broadest portfolio of Alzheimer's tests, Labcorp is proud to make the FDA...